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Natural killer (NK) cells rapidly reconstitute following allogeneic stem cell transplantation
(allo-SCT), at the time when alloreactive T cell immunity is being established. We inves-
tigated very early NK cell reconstitution in 82 patients following T cell-depleted allo-SCT.
NK cell number rapidly increased, exceeding T cell reconstitution such that the NK:T cell
ratio was over 40 by day 14. NK cells at day 14 (NK-14) were donor-derived, intensely pro-
liferating and expressed chemokine receptors targeted to lymphoid and peripheral tissue.
Spontaneous production of the immunoregulatory cytokine IL-10 was observed in over
70% of cells and transcription of cytokines and growth factors was augmented. NK-14 cell
number was inversely correlated with the incidence of grade II-IV acute graft versus host
disease (GVHD). These findings reveal that robust reconstitution of immunoregulatory NK
cells by day 14 after allo-SCT is an important determinant of the clinical outcome, sug-
gesting that NK cells may suppress the development of the T cell-mediated alloreactive
immune response through production of IL-10.
Keywords: Allo-SCT  GVHD  IL-10  NK cells  T cells depleted
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Over 30,000 patients undergo allogeneic stem cell transplan-
tation (allo-SCT) each year, the great majority as a treatment
for haemopoietic malignancy [1]. The curative potential of allo-
SCT is mediated by the ‘graft versus leukemia’ effect (GVL),
Correspondence: Dr. Paul Moss
e-mail: p.moss@bham.ac.uk
predominantly mediated by the alloreactive donor T cell response.
However, this immune response can also lead to severe tissue dam-
age in the patient through the action of acute GVHD [2, 3].
NK cells are an important component of the innate cellular
immune response and exhibit strong cytolytic and cytokine activity
against tumour cells and virally-infected cells [4, 5]. However,
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NK cells also have important regulatory functions [6] and localise
with haemopoietic cells within secondary lymphoid compartments
and at sites of inflammation [7, 8], where they can modulate the
adaptive T cell response through cytokine release, cytotoxicity or
promotion of antigen cross-presentation to T cells [8].
NK cells reconstitute early following allo-SCT [9, 10] and high
NK cell number at day 30–60 after transplantation is associated
with a reduced rate of disease relapse and improved overall sur-
vival [11–13]. Furthermore, infusion of NK cells protects against
acute GVHD whilst retaining GVL in murine models [14, 15].
These observations suggest that NK cells have the potential to
suppress the development of T cell mediated acute GVHD through
undefinedmechanisms without compromising the beneficial effect
of allo-SCT. Indeed, robust NK cell reconstitution has been seen
to predict for a lower risk of acute GVHD [12–14].
We undertook a detailed assessment of the function and pheno-
type of NK cells within the first 2 weeks after transplant, and cor-
related this with the clinical outcome. We demonstrate that donor
NK cells proliferate intensively during this period and become
targeted to secondary lymphoid and peripheral tissues through
expression of a range of chemokine receptors. Moreover they
exhibit very high expression of IL-10 in a pattern that mirrors
the ‘proliferation-induced conditioning’ observed within murine
NK cells and which acts to suppress adaptive immunity. Impor-
tantly, higher numbers of NK cells at 14 days after transplant are
associated with a reduced risk of acute GVHD.
Results
NK cells reconstitute rapidly following allo-SCT
The pattern of NK cell reconstitution was examined in a cohort of
82 consecutive patients that underwent allo-SCT using mobilised
peripheral blood (Table 1). 87% of patients received a RIC trans-
plant whereas 13% underwent myeloablative conditioning. 32%
of patients received HLA-identical transplants from siblings and
the remaining 68% received transplants from unrelated donors.
All patients received T cell depletion, 13% with ATG and 87%
with alemtuzumab, and both ciclosporin and methotrexate were
used for GVHD prophylaxis according to standard protocols. At
100 days the cumulative incidence of grade II-IV acute GVHD
was 25% and the incidence of chronic GVHD, relapse, transplant-
related mortality (TRM) and overall survival at 3 years was 29,
30, 20 and 53% respectively (Table 2).
Flow cytometry was used to define the reconstitution of NK
and T cells up to 100 days following allo-SCT (Gating strategy in
Fig. S1). The number of NK and T cells fell markedly in the first
week following transplantation (Fig. 1A and B) but subsequent
recovery was dramatic in NK cells, which reached pre-transplant
(D-7) levels within 28 days (Fig. 1A). In contrast, T lymphocytes
reconstituted to only 40% of pre-transplant levels by day 100 (Fig.
1B). The ratio of NK to T cells (NK:T) was approximately 1 prior
to transplantation, higher than the NK:T ratio of 0.17 in healthy
individuals [16]. The NK:T ratio further increased dramatically
Table 1. Patient and transplant characteristics and GVHD prophylaxis
Number %
Patient details
Age at transplant Median years
(range) (IQR)
52.5 (17–71)
(44-61)
Sex Male 52 63.4
Female 30 36.6
Diagnosis AML/MDS 43 52.4
NHL 13 15.9
ALL 12 14.6
AA 4 4.9
MF 3 3.7
HL 3 3.7
CLL 2 2.4
MPD 2 2.4
Sorror score 0 63 76.8
 1 19 23.2
Disease risk Low 14 17.1
Index Intermediate 36 43.9
High 29 35.4
Very High 3 3.7
Transplant details
Intensity Reduced intensity 71 86.6
Myeloablative 11 13.4
CMV at risk Yes 67 81.7
Male female
mismatch
Yes 20 24.4
Donor Unrelated 56 68.3
Sibling 26 31.7
HLA mismatch None 68 82.9
One 14 17.1
Stem cell source PBSC 82 100
GVHD prophylaxis
T cell depletion ATG 11 13.4
Alemtuzumab 71 86.6
Methotrexate Yes 14 17.1
Ciclosporin Yes 82 100
AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; NHL,
non-Hodgkin’s lymphoma; ALL, acute lymphoblastic leukaemia; AA,
aplastic anaemia; MF, myelofibrosis; HL, Hodgkin’s lymphoma; CLL,
chronic lymphocytic leukaemia; MPD, myeloproliferative disease; ATG,
anti-thymocyte globulin; MF mismatch, male female mismatch; HLA,
human leukocyte antigen; PBSC, peripheral blood stem cell. CMV at risk
is defined as either patient or donor being CMV positive.
Table 2. Patient outcomes
Cumulative incidence or overall
survival (95% CI)
Grade II-IV acute GVHD at
100 days
25% (16–35%)
Chronic GVHD at 3 years 29% (20–40%)
Relapse at 3 years 30% (20–40%)
TRM at 3 years 20% (11–29%)
Survival at 3 years 53% (39–73%)
C© 2017 The Authors. European Journal of Immunology published by
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Figure 1. The reconstitution of NK cells in the very early period following allo-SCT. PBMCs were isolated by density centrifugation. Mononuclear
cells were incubated with surface antibodies on ice for 20 min with Propidium iodide (PI) as viability dye. The percentage of the different cell
populations was assessed by Flow cytometry. (A) Reconstitution of the number of NK cells in the first 100 days following allo-SCT (B) Reconstitution
of the number of T cells in the first 100 days following allo-SCT. (C) Ratio of NK cell: T cell number up to 100 days. (D) CD56dim NK cells and (E)
CD56bright NK cells expressed as a percentage of the total NK cell population in the first 100 days following allo-SCT. (F) The ratio of CD56dim NK
cells: CD56bright NK cells plotted following allo-SCT. Data are pooled from 20 to 82 independent patients staining . All graphs depict mean and error
bars represent the standard error of the mean. Day -7 (n = 20), Day 7 (n = 82), Day 14 (n = 82), Day 28 (n = 20), Day 100 (n = 23). **p < 0.01, ***p < 0.005,
two-tailed, unpaired Mann–Whitney test. (G) Diagrammatic representation contrasting the ratio of CD56bright and CD56dim NK cells compared to T
cells at day 14 following allo-SCT in comparison to healthy donors.
after transplant such that NK cells outnumbered T cells by over
40 fold at day 14. The NK:T ratio remained higher than a healthy
individual even at 100 days post-transplant (Fig. 1C).
CD56 expression is used to distinguish two subpopulations of
NK cells with functional differences [4] and CD56bright NK cells
are regarded as less cytotoxic and less mature in comparison to
CD56dim populations. CD56dim NK cells comprised 78% of the
total NK cell population prior to therapy, increasing slightly to
88% by day 14 before dropping to 75% at day 28 (Fig. 1D). In
contrast, CD56bright NK cells (Fig. 1E) comprised 22% of the NK
repertoire before transplantation, falls to 12% at day 14 and then
expands to 25% at day 28 and 31% by day 100. As such the
CD56dim:CD56bright ratio (Fig. 1F) of 8.4 prior to treatment rose to
22 by D14 reflecting an increase in the proportion of mature NK
cells. The dramatic difference in the proportion of CD56bright NK
cells and CD56dim NK cells relative to T cells at day 14 compared to
healthy donors is displayed in Fig. 1G. Interestingly, in an analysis
T cell replete transplants the CD56bright NK cell subset at day 14
was significantly larger than that seen in TCD transplants at D14
(p < 0.001) (Supporting Information Fig. 2).
NK cells at day 14 express higher levels of NKG2A and
reduced expression of NKG2C
We next went on to examine the phenotype of NK cells at day
14 (NK-14) relative to the profile of NK cells from healthy donors
(Fig. 2A). NKG2A expression was markedly increased on both
the CD56dim and CD56bright populations at day 14. In particular,
NKG2A expression was observed on 23 and 46% of CD56dim and
C© 2017 The Authors. European Journal of Immunology published by
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Figure 2. Phenotypic changes seen on NK cells
during very early reconstitution after allo-SCT.
PBMCs were isolated by density centrifugation.
Mononuclear cells were incubated with surface
antibodies on ice for 20 min with Propidium iodide
(PI) as viability dye. The percentage of the different
cell populations was assessed by flow cytometry.
(A) Cell surface marker expression on NK cells at
day 14 after allo-SCT (NK-14) and NK cells within
healthy donors. Cell surface marker expression on
both the (B) CD56dim and (C) CD56bright NK cell sub-
sets. (D) Chemokine receptor expression on the
total NK cell population as well as (E) the CD56dim
and CD56bright NK cell subsets. (A–C): NK-14 (n= 82)
and healthy donors (n = 12). (D and E): NK-14 (n =
32) and healthy donors (n = 12). Data are pooled
from 12 to 82 independent patients staining. For
all graphs, the mean and standard error of the
mean are depicted. *p < 0.05, **p < 0.01; ***p < 0.005,
two-tailed, Mann–Whitney test for unpaired anal-
yses, Wilcoxon matched-pairs signed rank test for
paired analyses between CD56bright and CD56dim
NK cell subsets.
CD56bright NK cells within healthy donors whereas this increased to
47 and 70% on NK-14 cells. An inverse relationship was found for
the activating receptor NKG2Cwith higher expression observed for
both CD56dim and CD56bright populations in the control group (9
and 15% respectively) compared to our patient cohort (4 and 4%).
This increase in expression of NKG2A, and associated reduction
in expression of NKG2C, would suggest a more immature pheno-
type of NK-14 cells although this is unexpected given the relative
expansion of CD56dim cells. Expression of CD57, associated with a
terminally differentiated phenotype, showed a differential pattern
of staining on NK-14 cells. The expression of CD57 on CD56bright
cells increased from 21% within healthy donors to 31% in the
patient group. In contrast, expression of CD57 on CD56dim cells
at day 14 decrease from 61% within healthy donors to 43% in
the patient group. The expression of CD16 and KIR was similar
in patient and healthy donor groups and between CD56dim and
CD56bright populations. (Fig. 2B and C).
Expression of chemokine receptors on NK-14 cells
We then examined the expression of a range of chemokine recep-
tors that determine the ability of cells to traffic to tissue sites. Anal-
ysis included three receptors for homeostatic chemokines (CCR7,
CXCR4 and CCR9), receptors for chemokines that guide cells to the
gastrointestinal tract (CCR9, CCR5 and CCR6) or skin (ChemR23,
CX3CR1 and CXCR3) (Fig. 2D and E). Interestingly, homeostatic
chemokine receptor expression was relatively low on NK cells
from healthy donors, although CCR7 and CCR9 were expressed
on around 20% of CD56bright cells. Expression of receptors for the
homeostatic chemokines was markedly increased on NK-14 cells
with the most dramatic increase in the expression of CXCR4, rising
from 1%on healthy donor NK cells to 13% of D14-NK cells. Expres-
sion of these three receptors was higher on the CD56bright NK cell
subset within healthy donors, and although this differential pat-
tern was largely retained on NK-14 cells. The overall increase in
receptor expression on NK-14 cells is so great that levels observed
on patient CD56dim subsets exceeded values on CD56bright cells
from healthy donors in many cases.
More variation was observed in the pattern of expression of
receptors for chemokines that guide trafficking to the skin and
gastrointestinal tract. In addition to the increase in CCR9, expres-
sion of CCR5 was increased from 2% of cells in healthy donors to
7% on NK-14 samples. In contrast, expression of CCR6, the ligand
for MIP-3α, fell from 21% on healthy donor cells to 5% on NK-14
populations.
NK cells at day 14 are derived from the donor and are
undergoing intense proliferation
We next went on to investigate the origin and phenotype of
NK-14 cells in more detail. Microsatellite chimerism analysis was
C© 2017 The Authors. European Journal of Immunology published by
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Figure 3. The functional profile of NK cells at day 14 after allo-SCT. NK cells were enriched from freshly isolated PBMCs using the EasySepTM
HumanNKCell Enrichment Kit (STEMCELL Technologies). PurifiedNK cells were analyzed bymicro-satellite analysis at theWestMidlands Regional
Genetics Laboratory to assess chimerism status and by flow cytometry. (A) Example plot of KI-67 staining in one NK-14 and NK cells from one
healthy donor. (B) Comparison of Ki-67 expression in NK-14 (n = 5) and NK cells from HD (n = 5). (C) Example plot of intracellular staining of
TNFα, IFNγ and IL-10 from NK-14 and NK cells from healthy donors without stimulation. (D) Comparison of cytokines production in NK-14 and
NK cells from healthy donors without stimulation. (E) Multiple cytokines production in NK-14 and NK cells from healthy donors. (F) Comparison
of cytokines production between CD56bright and CD56dim NK-14 cell subsets. For all cytokine experiments: NK-14 (n = 11) and healthy donors (n
= 8). Data are pooled from 8 to 11 independent patients staining. (G) The cytotoxic activity of NK-14 (n = 5) and NK cells from healthy donors (n
= 5) was studied against K562 target cells at ratio 0.5:1. For all graphs the mean and standard error of the mean is depicted. *p < 0.05, **p < 0.01,
***p < 0.005, two-tailed, Mann–Whitney test for unpaired analyses, Wilcoxonmatched-pairs signed rank test for paired analyses between CD56bright
and CD56dim NK cell subsets.
C© 2017 The Authors. European Journal of Immunology published by
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performed on purified CD3−CD56+ cells taken at day 14 and
found NK-14 cells were derived exclusively from the transplant
donor (n = 3, data not shown). Given the remarkably high rate
of NK cell reconstitution we then determined the proliferative
status of the NK-14 cells through the use of Ki67 expression
(Fig. 3A). Although Ki67 was expressed in only 2.8% of NK cells
within healthy donors, virtually all NK-14 cells expressed Ki67
(Fig. 3B), reflecting an intense pattern of NK cell proliferation in
the early post-transplant period.
NK-14 cells demonstrate high levels of cytokine
production and retain cytotoxic function
To study the functional properties of NK-14 cells, we investigated
their profile of intracellular cytokine production and cytotoxic
potential in comparison to NK cells from healthy donors. Intra-
cellular staining for cytokine production was carried out initially
without prior stimulation of cells to assess baseline cytokine pro-
duction in cells analysed directly ex vivo. As anticipated, NK cells
taken from healthy donors displayed very low levels of cytokine
production in the absence of mitogenic stimulation. Specifically,
IL-10, IFN-γand TNFα production was seen in 1.5, 1.0 and 0.6%
of cells respectively. However, NK-14 cells were producing very
high levels of cytokines in vivo, measurable directly in an ex vivo
assay without mitogens. In particular, 71% of NK cells produced
IL-10, (p < 0.0001 versus healthy donors), 32% produced IFN-γ
(p < 0.0001) and 30% produced TNF-α (p < 0.0001) (Fig. 3C and
D). The serum concentration of IL-10 at day 14 was also around 4
fold higher compared to values within healthy controls although
no correlation was observed between this value and the incidence
of GvHD (Supporting Information Fig. 3).
We further examined the combinatorial profile of cytokine pro-
duction within NK-14 cells. The most common profile was that of
isolated IL-10 production, seen in 26% of cells, followed by com-
bined IL-10 and TNF-α or IL-10 and IFN-γ synthesis in 19 and 18%
of cells respectively. A further 7% of NK-14 cells were shown to
be spontaneously producing all three cytokines while no cytokine
production was seen in 20% of cells (Fig. 3E). Of note, only 9% of
cells showed evidence of TNF-α or IFN-γ production in the absence
of IL-10, indicating that an immunoregulatory profile is dominant
within NK-14 cells. Cytokine production is generally considered
to be feature of CD56bright rather than CD56dim NK cells and we
therefore examined the pattern of expression in these subsets in
NK-14 cells. Interestingly, this pattern was reversed and higher
levels of all three cytokines were observed within the CD56dim
subset (Fig. 3F).
NK-14 cells were enriched through the use ofmagnetic negative
selection and their cytotoxic activity against K562 target cells was
then determined using a flow cytometry-based cytotoxicity assay.
The 38% of target cells were lysed by NK cells from healthy donors
compared to 37%of cells when exposed to NK-14 populations (Fig.
3G). As such, NK-14 cells retain comparable levels of cytotoxic
potential compared to NK cells from normal donors.
Transcriptional activity within NK cells is markedly
downregulated at day 14
We next examined the transcriptional profile of NK-14 cells (n =
4) compared to NK cells from healthy donors (n = 5) to study
the functional profile of these cells further. Most transcripts were
expressed at a lower level in NK-14 cells compared with healthy
donors (Fig. 4A). Figure 4B displays differentially expressed genes
which demonstrate absolute log fold change > 1 and for which
the adjusted p-value is < 0.1 (full gene list in Supporting Infor-
mation Table 1). Gene set enrichment analysis demonstrated that
genes involved in transcription, cell cycle and RNA metabolism
were specifically enriched in the downregulated portion of the
transcriptome (–Log(FDR) 16.7, 17.9 and 31.3 respectively) (Fig.
4C right panel). There was also significant downregulation of gene
sets involved in NK cytotoxicity, the IFN-γ pathway and NK-related
transcription factors (Supporting Information Table 2). The most
significantly downmodulated genes included CARD8, which regu-
lates caspase activation, and the serine/threonine protein kinase
AKT3.
However, although the transcriptional profile was generally
downregulated, genes for cytokines and growth factors, defensins
and extracellularmatrix proteins were enrichedwithin the upregu-
lated transcripts (-Log(FDR) 21.3, 2.7 and 16.4 respectively) (Fig.
4C left panel). IL-10 gene transcripts are upregulated in the NK-
14 cells by a factor of around 1.2 fold compared to NK cells from
healthy donors and the specific position of IL-10 within the upreg-
ulated cytokine and growth factor transcripts is shown in a bar-
code plot (Fig. 4D). qRT-PCR data confirmed the upregulation of
IL-10 transcription in NK-14 cells compared with healthy donors
(Fig. 4E). The most significantly upregulated gene is KIR3DX1
(5.5-fold in NK-14 cells compared to HD) which is a killer cell
immunoglobulin-like receptor with unknown function.
NK-14 cell number predicts the risk of acute GVHD
and overall survival
Given the extreme numerical dominance of NK cells over T cells in
the early post-transplant period we then investigated if the recon-
stitution of NK cells was related to the clinical outcome of the
procedure. We first assessed whether the number of NK cells at
day 7, 14, 28 and 100 days post-transplant could discriminate
the subsequent risk of acute GVHD, transplant-related mortality,
relapse rate and overall survival. Receiver operating curves were
plotted to assess the absolute NK cell count at various time points
following SCT and its ability to discriminate between the clinical
end-points of: aGVHD, OS, relapse and transplant related mor-
tality. A p-value< 0.05 was used as the threshold for statistical
significance. A significant association was seen between the num-
ber of NK cell at day 7 and 14 and acute GVHD, and with the NK
number at day 14 and reduced overall survival. A higher rate of
relapse was associated with lower number of NK cells at day 7 but
this effect was lost by day 14 (Fig. 5A).
C© 2017 The Authors. European Journal of Immunology published by
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Figure 4. The transcriptional profile of NK cells at day 14 following allo-SCT compared to healthy donor NK cells. (A) The NK cells were enriched,
total RNA was extracted, labelled and hybridized to GeneChip R© Human Transcriptome array 2.0 (Affymetrix, USA). Volcano plot demonstrating
overall transcript profile of D14-NK (n= 4) compared to NK cells from healthy donors (n= 5). The expression of genes shown to the left is reduced in
NK-14 and those to the right are increased. (B) Heatmap displaying the differentially expressed genes between D14-NK and NK cells from healthy
donors (absolute log2 FC> 1 and adjusted p-value of< 0.1). (C) Gene set enrichment analysis shows that the genes for cytokines and growth factors,
defensins and extracellular matrix proteins were specifically enriched in the upregulated transcripts, whilst genes involved in transcription, cell
cycle and RNA metabolism were enriched in the downregulated genes. (D) A barcode plot highlighting enrichment of cytokines and growth factor
genes, including IL-10 within the upregulated transcripts. (E) The NK cells were enriched, total RNA was extracted and the transcription of IL-10
(normalized by GAPDH transcription level) was studied with D14-NK (n-5) and NK cells from HD (n = 5) through qRT-PCR. Data are pooled from
three independent experiments. PCRs performed in five different donors. Data are represented as mean and error bars refer to standard error. The
difference between was analyzed by Mann–Whitney test, with **P < 0.01.
We went on to investigate the association between NK cell
number and acute GVHD in more detail. Receiver operating char-
acteristic (ROC) curve analysis demonstrated that the absolute
NK cell count at D7 and D14 could discriminate the risk of acute
GVHD with an area under curve (AUC) value of 0.68 (p < 0.05;
95% CI 0.54–0.82) and 0.66 (p< 0.05; 95% CI 0.51–0.80) respec-
tively (Supporting Information Fig. 5). In addition to the total NK
cell count, the absolute counts of several NK cell subsets were also
predictive at these early time points (D7: CD56bright, CD56dim,
NKG2A+, NKG2C+, KIR+, CD57+ and CD16+; D14: CD56dim,
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co.KGaA, Weinheim.
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Figure 5. The magnitude of NK cell reconstitution in the first two weeks following allo-SCT is predictive for the subsequent risk of acute GVHD
and OS. (A) Receiver operating curves were plotted to assess the absolute NK cell count at various time points following SCT and its ability to
discriminate between the clinical end-points of: aGVHD, OS, relapse and transplant related mortality. A p-value < 0.05 was used as the threshold
for statistical significance (dash line). The p value (Y axis) versus NK number at different time points (D7, D14, D28, D100) (X axis) were plotted to
demonstrate the association of NK number with different clinical outcomes. (B) Scatter plot (Mann-Whitney test) to compare the NK number in
the patients who developed acute GVHD and who did not develop acute GVHD. Dash line indicates the NK cell count of 25 cells/μl at day 14. (C)
Cumulative incidence curve (Fine and Gray test) to compare the incidence of acute GVHD between different D14-NK cell number group (cut-off
point as 25 cell/μL). P < 0.05. There are 52 patients in the group with NK cell number< 25 cell/μL and 30 patients in the group with NK cell number
> 25 cell/μL. (D) Kaplan-Meier curve (log-rank test) to compare the overall survival between different D14-NK cell number group (cut-off point as
25 cell/μL).
NKG2A+ and NKG2C+(Supporting Information Table 3)) but no
single subset was uniquely associated.
NK-14 < 25 cells/μL is an independent predictor of
acute GVHD in multivariate analyses
As we have shown the significant association between the num-
ber of NK cell at day 14 and acute GVHD, the NK-14 number
between the patients who developed acute GVHD and who did
not develop acute GVHD were compared. The median NK number
in the patients who developed acute GVHD was 5 cells/μL com-
pared with 20 cells/μL in those who did not develop acute GVHD
(Fig. 5B).
Using the ROC curve, we were able to appreciate how chang-
ing the cut off NK-14 cell number used affected the sensitivity and
specificity of the predictive test. We chose a cut off NK-14 count
of 25 cells/uL for univariate and multivariate analysis as this pro-
vided a high sensitivity (85%) for predicting acute GVHD with
a specificity of 44%. In multivariate analysis, NK cell number of
< 25 cells/μL, HLA-mismatch and conditioning intensity remained
independently associated with an increased risk of acute GVHD (p
= 3.5 × 10−2, p = 5.1 × 10−6 and p = 9.1 × 10−4 respectively)
(Table 3 and Fig. 5C). Patients who achieved this cell count at day
14 also showed a trend towards increased survival but this was
not significant (Fig. 5D). An NK-14 cell count of > 25 cells/μL
was not associated with any differences in chronic GVHD, disease
relapse, relapse mortality or transplant-related mortality (Sup-
porting Information Fig. 6A 6B 6C and 6D).
Using a lower NK-14 cut off of 5 cells/μL increases the speci-
ficity of the predictive test, although there is a reciprocal decrease
in the sensitivity. Interestingly, we found that patients with an NK-
14 cell count of < 5 cells/uL demonstrated significantly reduced
overall survival (Supporting Information Fig. 6E) on both univari-
ate and multivariate analysis, indicating that a relatively low level
of NK reconstitution is sufficient to deliver a survival advantage
with incremental improvements in NK recovery associated with
additional improvements in patient outcome following allo-SCT.
Discussion
Immunological processes determine the majority of the clinical
features of allo-SCT but the mechanisms of immune regulation
after transplant are poorly understood despite 40 years of clinical
practice [17]. The rapid reconstitution of NK cells is a character-
istic feature of allo-SCT [18] and whilst donor T cells are crucial
in the alloreactive immune response [19, 20] there is growing
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Table 3. Factors predicting development of acute GVHD (grades II–IV)
HR 95% CI P-value
Univariate analysis
Age < 50 1
 50 0.496 0.208–1.18 0.11
Sex Male 1
Female 0.976 0.392-2.43 0.96
Diagnosis myeloid 1
lymphoid 1.53 0.639-3.65 0.34
marrow failure 0.734 0.112-4.8 0.75
Sorror score 0 1
 1 2.11 0.856-5.19 0.1
DRI low-int 1
high-v high 1.37 0.576-3.27 0.48
Intensity RIC 1
MA 4.24 1.81-9.96 9.1 × 10−4
CMV at risk Yes 0.888 0.3-2.62 0.83
No 1
Male female mismatch Yes 1.79 0.726-4.41 0.21
No 1
Donor Unrelated 1.99 0.676-5.86 0.21
Sibling 1
TCD Campath 1
ATG 1.07 0.34-3.4 0.9
HLA 0 1
mismatch  1 4.41 1.81-10.7 0.0011
D14-NK < 25 3.52 1.02-12.1 0.046
 25 1
Multivariate analysis
Conditioning RIC 1
MA 6.759 2.19-20.9 9.1 × 10−4
HLA mismatch 0 1
 1 16.495 4.94-55.0 5.1 × 10−6
D14-NK < 25 5.81 1.13-29.8 3.5 × 10−2
 25 1
The Fine and Gray model for subdistributional hazard based on the cumulative incidence function was used with death as a competing risk for
development of aGVHD. A landmark approach was required with time from day 14 to development of aGVHD used for analysis. DRI, disease risk
index; RIC, reduced intensity conditioning; MA, myeloablative; TCD, T cell depletion.
appreciation of the importance of NK cells in determining clinical
outcome [21]. We focussed our studies within the first two weeks
after transplantation as this early phase of immune reconstitution
has been relatively poorly investigated and yet plays a critical role
in determining the profile of alloreactive immunity and clinical
outcome.
Our findings confirm that NK cells recover rapidly following
T cell depleted allo-SCT [9, 10]. This expansion, at a time when
T cell numbers are highly suppressed, leads to a profound alter-
ation in the ratio of NK and T cells within peripheral blood. In
healthy individuals the NK:T cell ratio is approximately 0.17,
whereas at day 14, NK cells outnumber T cells by 40 to 1, repre-
senting a greater than 200 fold change in NK:T cell ratio. It should
be noted that the transplant conditioning regimens in our study
incorporated T cell depletion as a strategy to reduce the risk of
GVHD [22, 23].
We identified a biphasic pattern of reconstitution within NK
cell subsets. There was an initial slight increase in the propor-
tion of CD56dim NK cells at day 14 and subsequent expansion
of CD56bright NK cells, to 31% of the NK cell population by day
100. The expansion of mature CD56dim NK cells likely represents
homeostatic proliferation of donor NK cells adoptively transferred
within the stem cell product whereas the subsequent increase of
the less mature CD56bright NK cell population probably reflects de
novo production of NK cells from donor stem cells [11].
Remarkably, almost all NK-14 cells were undergoing prolif-
eration, compared to less than 3% of healthy donor cells. This
reflects intense homeostatic proliferation and has been observed
in lymphopenic mouse models [24, 25]. IL-15 is critical for NK
proliferation and survival and, as serum IL-15 levels rise in the
first two weeks following allo-SCT, is also likely to represent an
important mechanism following transplantation [26].
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NK-14 cells display increased expression of NKG2A and lower
levels of CD57 on the CD56dim subset. This phenotypic profile
has similarities with cytokine-induced memory-like (CIML) NK
cells, which are induced in vitro by IL-12, IL-15 and IL-18 stimula-
tion [27]. Allo-SCT conditioning is associated with high cytokine
levels, sometimes termed the ‘cytokine storm’, and NK-14may rep-
resent the in vivo correlate of CIML [28]. Functional similarities
include vigorous cytokine production. CIML NK cells are potent
anti-leukaemia effector cells [29] and it is possible that NK-14
play an important role in the GvL response as we also demon-
strated that D14-NK cells retain levels of cytotoxic activity that are
comparable to healthy donors.
NK-14 cells express increased levels of chemokine receptors,
including CCR7 which guides trafficking to lymph nodes [30],
CXCR4 which mediates bone marrow homing [31] and CCR9
which directs cells towards the thymus and gastrointestinal tract
[32]. Overall, NK-14 cells acquire the ability to enter a range of
lymphoid and peripheral tissues.
Perhaps the most striking feature of NK-14 cells was the pat-
tern of intense and spontaneous cytokine production. This pro-
file was observed without mitogenic stimulation in vitro, was not
demonstrable in cells isolated from healthy donor and has been
noted in murine models during homeostatic proliferation [33].
IL-10 was the dominant cytokine, being expressed in 70% of
NK-14 cells in comparison to IFN-γ or TNF-α expression in less
than half of this proportion. Interestingly, NK cells isolated at day
28 following HSCT continued to demonstrate spontaneous pro-
duction of IL-10 within 0.34% of cells, compared to 0.06% of
healthy donors (p < 0.05), although this does demonstrate a rela-
tively short timecourse of IL-10 production in the post-transplant
period (Supporting Information Fig. 4). This pattern has similari-
ties with murine models studied by Tarrio and colleagues [34]. In
these models, homeostatic proliferation leads to epigenetic repro-
gramming of the IL-10 locus and a switch to IL-10 production in a
phenomenon termed ‘proliferation-dependent conditioning’ of NK
cells. This switch from an inflammatory to regulatory phenotype
utilizes the high frequency of NK cells to apply negative pressure
on the adaptive immune system. IL-10 production by proliferat-
ing human NK cells has also been demonstrated in vitro following
incubation with both IL-2 and IL-12 [35].
IL-10 is an anti-inflammatory mediator that is vital in limiting
immunopathology [35–37] and can also suppress NK-mediated
licensing of DC activation [38] and modulate NK deletion of
DCs [39]. Our finding that NK cells strongly outnumber T
cells, express high levels of IL-10 and can migrate to secondary
lymphoid tissue together indicate that they may suppress the
generation of the T cell mediated alloreactive immune response.
Furthermore, immunoregulatory NK cells within peripheral tissues
may serve to limit tissue damage mediated by alloreactive effector
cells. The ability of NK cells to directly kill antigen presenting
cells (DCs) or activated T cells may also play an important role
[21, 40–42].
Allo-SCT is a therapeutic intervention and is profoundly differ-
ent to physiological or pathophysiological processes encountered
during evolution. However, IL-10 production within NK cells has
been demonstrated following systemic infections and the induc-
tion of IL-10 production in NK-14 cells may represent an exten-
sion of the physiological response to regulate inflammation follow-
ing episodes of moderate lymphopenia during infection [43, 44].
Although our study is focused on patients undergoing allo-SCT,
our findings provide further insight into the normal physiological
function of NK cells.
Microarray analysis demonstrated a predominant profile of
‘transcriptional exhaustion’ within NK-14 cells, with marked
downregulation in the expression of most genes. Human NK cells
have a turnover time of around 2 weeks within blood [45] and
thus many cells will be undergoing senescence following 14 days
of intense activation and proliferation. However, genes associ-
ated with cytokines and growth factors, defensins and extracellu-
lar matrix proteins were selectively enriched within upregulated
transcripts, corroborating our findings that NK-14 cells are func-
tional cytotoxic cells demonstrating prolific cytokine production.
The mRNA level of the KIR gene KIR3DX [46] was increased by
5.5 fold in NK cells at day 14 and whilst the function of KIR3DX1
is unknown.
Our study investigated whether the temporal profile of NK cell
reconstitution correlated with clinical outcome. The association
between NK cell reconstitution and acute GVHD and overall sur-
vival was seen only with NK cell number at day 7 and day 14,
and was subsequently lost when the NK count was determined
at day 28 and day 100. Therefore, the expansion and function of
the mature donor NK cells infused with the stem cell graft play
a dominant role in determining transplant success. The whole
NK-14 cell population was implicated, as we did not identify a
specific subset of NK cells responsible for determining the relation-
ship with clinical outcome. Although it is intuitive to expect that
the NK-14 cell count is dependent on the absolute number of NK
cells infused within the stem cell graft, this correlation was not sta-
tistically significant (data not shown). Therefore, factors present
within the patient, such as cytokine levels, maybe more influential
in determining whether a patient reconstitutes sufficient NK cells
to provide protection from adverse outcome. Importantly, lower
NK-14 cell numbers were not associated with an increased risk
of relapse, indicating retention of the GVL response and consis-
tent with other studies demonstrating that NK cells can dissociate
GVHD and GVL [12, 15].
In conclusion, higher numbers of NK-14 cells are strongly corre-
lated with a reduced risk of acute GVHD and our finding that such
cells express high levels of IL-10, and are targeted to lymphoid
and peripheral tissue, provides a direct mechanism for this associ-
ation (Fig. 6). NK cells may traffic to the lymph node, where IL-10
could suppress the generation of alloreactive T cell responses, or
their effect may be mediated by suppression of alloreactive T cells
within peripheral tissue. These findings have relevance for clinical
practice. NK-14 cell number may be a biomarker for clinical out-
come, particularly when combined with additional measures such
as serum analysis [47] or T cell count [48, 49]. Furthermore, opti-
misation of early donor NK cell engraftment may impact on patient
outcome, possibly through graft engineering or by manipulation
of the cytokine microenvironment.
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Figure 6. Diagram to show donor NK cells that produce IL-10 in the early post transplant period suppress the development of acute GVHD in
patients undergoing allo-SCT. Mature NK cells are transferred from the donor to the patient at the time of stem cell infusion and undergo intense
homeostatic proliferation and a switch to an immunoregulatory phenotype with dominant spontaneous production of IL-10. These NK cells
express chemokine receptors required for migration to secondary lymphoid tissues, where they are likely to play an important role in suppressing
the development of alloreactive T cells, or to peripheral tissues where theymay limit T cell damage. (This figure has been produced using resources
from Servier Medical Art).
Materials and methods
Patients and sample collection
NK cell reconstitution was examined in a cohort of 82 consecu-
tive patients who underwent allo-SCT using mobilised peripheral
blood. Patients received either alemtuzumab (10 mg/kg × 5 days)
or anti-thymocyte globulin (ATG) prior to stem cell infusion as in
vivo T cell depletion. The clinical characteristics and transplant
details for patients in the study are summarised in Table 1. RIC
and myeloablative conditioning regimes were defined using pub-
lished guidelines [50]. HLA typing was determined at HLA-A, -B,
-C, -DRB1 and –DQB1 using high-resolution techniques. Unrelated
donors were either HLA matched (10/10) or mismatched at one
loci (9/10).
In addition to in vivo T cell depletion, patients received
ciclosporin +/- methotrexate for GVHD prophylaxis according to
local protocols. Ciclosporin was commenced pre-transplant, dose-
adjusted to achieve therapeutic levels and tapered from D+90 in
the absence of GVHD. The diagnosis and grading of acute GVHD
was carried out in accordance with consensus criteria [51].
Clinical data and samples were obtained after written informed
consent in accordance with the Declaration of Helsinki and
approved by the South Birmingham Research Ethics Commit-
tee (Q5/Q2707/175). Blood samples were taken 1 week pre-
transplantation and then at day 7 (range 5–8 days), day 14 (range
12–15 days), day 28 (range 3–5 weeks) and day 100 (range 3–4
months) post transplant.
Flow cytometry: surface marker phenotype,
chemokine receptor profile, cytokine production and
cell number estimation
The experiments with T cells in the study always followed the
MIATA (Minimal Information About T cell Assays) guidelines.
PBMCs were isolated by density centrifugation. Mononuclear
cells were incubated with surface antibodies on ice for 20 minutes
with Propidium iodide (PI) as viability dye. The antibodies for the
surface phenotype staining include Qdot655 conjugated anti-CD3
(clone S4.1, Invitrogen); APC-Cy7 conjugated anti-CD56 (clone
HCD56, Biolegend); V500 conjugated anti-CD16 (clone 3G8, BD
Biosciences); Pacific Blue conjugated anti-CD57 (clone HCD57,
Biolegend); PC5.5 conjugated anti-CD158a (clone EB6, Beckman
Coulter); PC7 conjugated anti-CD158b (clone GL18, Beckman
Coulter); AF700 conjugated anti-CD158e (clone DX9, Biolegend);
APC conjugated anti-NKG2A (clone Z199, Beckman Coulter); PE
conjugated anti-NKG2C (clone 134591, R & D systems).
The chemokine receptor staining included two panels. The
same antibodies (anti- CD3, CD56 and CD16) as surface phenotype
panel were used to gate NK cells. The chemokine receptor anti-
bodies from the first panel include: PerCPCy5.5 conjugated anti-
CXCR3 (clone 1C6, BD Biosciences); APC conjugated anti-CCR7
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(clone 150503, R & D Systems); PeCy7 conjugated anti-CCR5
(clone 2D7, BD Biosciences); FITC conjugated anti-ChemR23
(clone BZ332, Bio-Rad antibodies:formerly ABD serotec); AF700
anti-CXCR4 (clone 12G5, R & D Systems); PE conjugated anti-
CCR6 (clone G034E3, Biolegend). The chemokine receptors anti-
bodies from the second panel include: APC conjugated anti- CCR9
(clone 112509, R & D Systems) and PerCPCy5.5 conjugated anti-
CX3CR1 (clone 2A9-1, Biolegend)
Ex vivo cytokine production determined using the intracel-
lular antibodies panel, included: PE conjugated anti-CD3 (clone
UCHT1, Beckman Coulter); APC-cy7 conjugated anti-CD56 (clone
HCD56, Biolegend); Pe-Cy7 conjugated anti-TNFα (clone MAb11
eBioscience);
AF700 conjugated anti-IFNγ (clone 4S.B3, Biolegend); PE con-
jugated anti-IL-10 (clone JES3-19F1, Biolegend).
Data was acquired on an LSR-II flow cytometer and analysed
using FACSDiva software.
For samples taken at day –7, day 28 and day 100, lymphocyte
counts were available from clinical laboratory full blood counts.
Samples from day 7 and day 14 were estimated using BD Trucount
Tubes (BD Biosciences).
Chimerism analysis
NK cells were enriched from freshly isolated PBMCs using the
EasySepTM Human NK Cell Enrichment Kit (STEMCELL Tech-
nologies). Purified NK cells were analysed by micro-satellite anal-
ysis at the West Midlands Regional Genetics Laboratory to assess
chimerism status.
Ki-67 assay NK cells were isolated as described above. Ki-67
expression on the purified NK cell population was assessed using
the FITC Mouse Anti-Human Ki-67 Set (BD Pharmingen).
NK cell cytotoxicity assay
NK cells were purified using EasySepTM Human NK cell enrich-
ment kit (STEMCELL Technologies) (purity of sorted NK cells was
90–95% of CD3 negative and CD56 positive lymphocytes) and
activated. Meanwhile, K562 cells were stained with CFSE dye.
Labelled K562 cells were either incubated with RPMI (negative
control) or with activated NK cells at a E/T ratio of 0.5:1 for 16
h. Cells were subsequently extracted and a fixed volume analysed
on the BD AccuriTM flow cytometer (BD Bioscience) to gain an
absolute cell count.
% specific lysis was calculated by 100 × {1 − [(experimental
group cell count)/(control cell count)]}. PI was used to gate the
live populations.
Gene expression profiling
Magnetically isolated NK cells were stainedwith anti-CD3 PE, anti-
CD56 APC-Cy7, and CD3- and CD56+ live cells were sorted with
the Astrios cell sorter (BD Biosciences) as an added enrichment
step. The purity of the sorted NK population was 99% of CD3
negative and CD56 positive lymphocytes. The sorted NK cell pop-
ulations were sent to AROS Applied Biotechnology A/S (Aarhus
N, Denmark) as dry cell pellets. Total RNA was extracted, labelled
and hybridized to GeneChip R© Human Transcriptome array 2.0
(Affymetrix, USA). Microarray data is available in the Array-
Express database (www.ebi.ac.uk/arrayexpress) under accession
number E-MTAB-5474. Raw data was processed using Affymetrix’s
Expression Console software using default RMA parameters. Sta-
tistical analysis of differential expression was performed using the
R package limma with Benjamini-Hochberg method applied to
adjust p-values for multiple testing. Gene-set enrichment analysis
was performed using the Bioconductor R package GAGE. Curated
gene sets for canonical signaling pathways were obtained from
the Molecular Signalling Database.
Statistical analysis
Mann–Whitney’s non-parametric method was used to compare
healthy donor NK and D14-NK cells. The Wilcoxon matched pairs
signed rank test was used to compare CD56bright and CD56dim
NK cell subsets.
Receiver operating characteristic (ROC) curves were plotted to
assess the prognostic relationship between NK cell reconstitution
and grade II-IV acute GVHD. The area under the curve (AUC) and
95% confidence intervals for the NK cell subsets and time points
were compared and the NK cell population at day 14 (NK-14)
identified for further investigation.
A landmark approach was taken for all survival analyses, with
time from day 14 to clinical event used in analysis. The cumulative
incidence of grade II-IV acute GVHD was assessed in combination
with ‘death from any cause’ as a competing risk. Patients with NK-
14 < 25 NK cells/μL had an increased risk of acute GVHD (HR
3.52, 95% CI 1.02-12.1, p = 0.046)(Fig. 5B). HLA mismatch 1
(HR: 4.41, 95% CI: 1.81–10.7, p = 0.0011) and myeloablative
conditioning (HR: 4.24, 95% CI: 1.81–9.96, p = 9.1 × 10–4)
also significantly increased the risk of acute GVHD on univariate
analysis. The multivariate adjustment for factors predicting the
cumulative incidence of grade II-IV acute GVHD was performed
within the framework of competing risks using the Fine and Gray
method. Factors significant on univariate analysis were included in
the model. A competing risk approach was also taken in assessing
the effect on TRM (using death from relapse as the competing
event) and RR (using TRM as the competing event).
To investigate the effect of D14-NK cell reconstitution and clini-
cal variables on overall survival, survival curves were plotted using
the Kaplan-Meier method and assessed with the log-rank method.
The Cox proportional hazards model was used for multivariate
analyses.
All statistical tests were two-sided and the level of statistical
significance utilized was 0.05. Statistical analysis was carried
out using R (version 3.2.1 GUI 1.66 Mavericks build (6956)),
SPSS (IBM version 22) and Prism (GraphPad version 6.0b). For
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competing risk analysis, we used the cmprsk package and ccr-
addson function written for R (http://www.stat.unipg.it/luca/R).
Acknowledgements: Y.L.T.C. designed and performed experi-
ments; acquired samples and clinical data; acquired, analyzed and
interpreted data; and prepared the manuscript. J.Z. designed and
performed experiments; acquired, analyzed and interpreted data;
and prepared the manuscript. C.I., J.C. and F.K. M. assisted in
experimental design and data analysis. W.C. contributed to analy-
sis of microarray data and interpretation. L.M. and B.A. assisted in
sample collection. S.N. and J.N. assisted in sample collection and
acquisition of clinical data. C.C. and R.M. assisted in data inter-
pretation and experimental design. P.M. oversaw experiments
and data analysis and prepared the manuscript. All authors have
read and contributed to the manuscript. Y.L.T.C. is in receipt of
a Medical Research Council Clinical Research Training Fellow-
ship. The research was further supported by programmatic fund-
ing from Bloodwise (PI: Prof. Paul Moss, grant code: 12052) and
the Medical Research Council (PI: Prof Paul Moss, grant code:
MR/K021192/1). We would like to thank the patients who partic-
ipated in the study and who generously donated samples for our
research. We would also like to thank Dr Duncan Murray for his
support in statistical methodology.
Conflict of interest: The authors declare no financial or commer-
cial conflict of interest.
References
1 Niederwieser, D., Baldomero, H., Gratwohl, M., Aliurf, M., Atsuta, Y.,
Bouzas, L., Confer, D. et al., Hematopoietic stem cell transplantation
activity worldwide in 2012 and a SWOT analysis of the Worldwide Net-
work for Blood and Marrow Transplantation Group including the global
survey. Bone Marrow Transplant. 2016. 51:778–785.
2 Shlomchik, W. D., Graft-versus-host disease. Nat. Immunol. 2007. 7:340–
352.
3 Holtan, S. G., Pasquini, M. and Weisdorf, D. J., Acute graft-versus-host
disease : a bench-to-bedside update. Blood 2014. 124:363–374.
4 Caligiuri, M. A., Human natural killer cells. Blood. 2008. 112:461–469.
5 Ka¨rre, K., Ljunggren, H. G., Piontek, G. and Kiessling, R., Selective rejec-
tion of H-2-deficient lymphoma variants suggests alternative immune
defence strategy. Nature 1986. 319:675–678.
6 Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier,
L. L.,Yokoyama,W. M. et al., Innate or adaptive immunity? The example
of natural killer cells. Science 2011. 331:44–49.
7 Moretta, A., Marcenaro, E., Sivori, S., Della Chiesa, M., Vitale, M. and
Moretta, L., Early liaisons between cells of the innate immune system in
inflamed peripheral tissues. Trends Immunol. 2005. 26:668–675.
8 Martı´n-Fontecha, A., Thomsen, L. L., Brett, S., Gerard, C., Lipp, M., Lan-
zavecchia, A. and Sallusto, F., Induced recruitment of NK cells to lymph
nodes provides IFN-gamma for T(H)1 priming.Nat. Immunol. 2004. 5:1260–
1265.
9 Ullah, M. A., Hill, G. R. and Tey, S.-K., Functional Reconstitution of nat-
ural killer cells in allogeneic hematopoietic stem cell transplantation.
Front. Immunol. 2016. 7:144.
10 Chang, Y., Zhao, X. and Huang, X., Immune reconstitution after hap-
loidentical hematopoietic stem cell transplantation. Biol. Blood Marrow
Transplant. 2014. 20:440–449.
11 Pical-izard, C., Crocchiolo, R., Granjeaud, S., Kochbati, E., Just-landi, S.,
Chabannon, C., Frassati, C. et al., Reconstitution of natural killer cells
in HLA-matched HSCT after reduced-intensity conditioning : impact on
clinical outcome. Biol. Blood Marrow Transplant. 2015. 21:429–439.
12 Dunbar, E. M., Buzzeo, M. P., Levine, J. B., Schold, J. D., Meier-Kriesche,
H.-U. and Reddy, V., The relationship between circulating natural
killer cells after reduced intensity conditioning hematopoietic stem cell
transplantation and relapse-free survival and graft-versus-host disease.
Haematologica 2008. 93:1852–1858.
13 Savani, B. N., Mielke, S., Adams, S., Uribe, M., Rezvani, K., Yong, A. S.
M., Zeilah, J. et al., Rapid natural killer cell recovery determines outcome
after T-cell-depleted HLA-identical stem cell transplantation in patients
with myeloid leukemias but not with acute lymphoblastic leukemia.
Leukemia 2007. 21:2145–2152.
14 Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D.,
Tosti, A., Posati, S. et al., Effectiveness of donor natural killer cell
alloreactivity in mismatched hematopoietic transplants. Science 2002.
295:2097–2100.
15 Asai, O., Longo, D. L., Tian, Z. G., Hornung, R. L., Taub, D. D., Ruscetti,
F. W. and Murphy, W. J., Suppression of graft-versus-host disease and
amplification of graft-versus-tumor effects by activated natural killer
cells after allogeneic bone marrow transplantation. J. Clin. Invest. 1998.
101:1835–1842.
16 Bisset, L. R., Lung, T. L.,Kaelin, M., Ludwig, E. andDubs, R.W., Reference
values for peripheral blood lymphocyte phenotypes applicable to the
healthy adult population in Switzerland. Eur. J. Haematol. 2004. 72:203–
212.
17 Thomas, E. D., Bucker, C. D., Banaji, M.,Clift, R. A., Fefer, A., Flournoy, N.,
Goodell, B. W. et al., One hundred patients with acute leukemia treated
by chemotherapy, total body irradiation, and allogeneic marrow trans-
plantation. Blood 1977. 49:511–533.
18 Ault, B. Y. K. A., Antin, J. H., Ginsburg, D., Orkin, S. H., Rappeport, J.
M., Keohan, M. L. O. U., Martin, P. et al., Phenotype of recovering lym-
phoid cell populations after marrow transplantation. J. Exp. Med. 1985.
161:1483–1502.
19 Apperley, J. F., Jones, L., Hale, G., Waldmann, H., Hows, J., Rombos,
Y., Tsatalas, C. et al., Bone marrow transplantation for patients with
chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces
the incidence of graft-versus-host disease but may increase the risk of
leukaemic relapse. Bone Marrow Transplant. 1986. 1:53–66.
20 Mielke, S., McIver, Z. A., Shenoy, A., Fellowes, V., Khuu, H., Stroncek,
D. F., Leitman, S. F. et al., Selectively T cell-depleted allografts from
hla-matched sibling donors followed by low-dose posttransplantation
immunosuppression to improve transplantation outcome in patients
with hematologic malignancies. Biol. Blood Marrow Transplant. 2011.
17:1855–1861.
21 Ruggeri, L.,Mancusi, A., Burchielli, E., Capanni, M., Carotti, A., Aloisi, T.,
Aversa, F. et al., NK cell alloreactivity and allogeneic hematopoietic stem
cell transplantation. Blood Cells. Mol. Dis. 2008. 40:84–90.
22 Shaw, B. E., Apperley, J. F., Russell, N. H., Craddock, C., Liakopoulou,
E., Potter, M. N., Wynn, R. et al., Unrelated donor peripheral blood stem
cell transplants incorporating pre-transplant in-vivo Alemtuzumab are
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co.KGaA, Weinheim.
www.eji-journal.eu
14 Yuen Ling Tracey Chan et al. Eur. J. Immunol. 2017. 0: 1–14
not associated with any increased risk of significant acute or chronic
graft-versus-host disease. Br. J. Haematol. 2011. 153:244–252.
23 Bacigalupo, A., Antilymphocyte/thymocyte globulin for graft versus host
disease prophylaxis: efficacy and side effects. Bone Marrow Transplant.
2005. 35:225–231.
24 Prlic, M., Blazar, B. R., Farrar, M. A. and Jameson, S. C., In vivo survival
and homeostatic proliferation of natural killer cells. J. Exp. Med. 2003.
197:967–976.
25 Jamieson, A. M., Isnard, P., Dorfman, J. R., Coles, M. C. and Raulet, D. H.,
Turnover and proliferation of NK cells in steady state and lymphopenic
conditions. J. Immunol. 2004. 172:864–870.
26 Cooper, M. A., Bush, J. E., Fehniger, T. A., VanDeusen, J. B., Waite, R.
E., Liu, Y., Aguila, H. L. et al., In vivo evidence for a dependence on
interleukin 15 for survival of natural killer cells. Blood 2002. 100:3633–
3638.
27 Romee, R., Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R.,
Sullivan, R. P., Cooper, M. A. et al., Cytokine activation induces human
memory-like NK cells. Blood 2012:4751–4760.
28 Melenhorst, J. J., Tian, X., Xu, D., Sandler, N. G., Scheinberg, P., Bian-
cotto, A., Scheinberg, P. et al., Cytopenia and leukocyte recovery shape
cytokine fluctuations after myeloablative allogeneic hematopoietic stem
cell transplantation. Haematologica 2012. 97:867–873.
29 Romee, R., Rosario, M., Berrien-elliott, M. M., Wagner, J. A., Jewell, B. A.,
Schappe, T., Leong, J. W. et al., Cytokine-induced memory-like natural
killer cells exhibit enhanced responses against myeloid leukemia. Sci.
Trans. Med. 2016. 8:357ra123.
30 Fo¨rster, R., Davalos-Misslitz, A. C. and Rot, A., CCR7 and its ligands:
balancing immunity and tolerance. Nat. Rev. Immunol. 2008. 8:362–371.
31 Mo¨hle, R.,Bautz, F.,Rafii, S.,Moore,M. A. S.,Brugger,W.,Kanz, L. and Sdf
T., The chemokine receptor CXCR-4 is expressed on CD34 + hematopoi-
etic progenitors and leukemic cells andmediates transendothelialmigra-
tion induced by stromal cell-derived factor-1. Blood 1998. 91:4523–4530.
32 Stenstad, H., Ericsson, A., Johansson-Lindbom, B., Svensson, M.,Marsal,
J.,Mack, M., Picarella, D. et al., Gut-associated lymphoid tissue – primed
CD4 + T cells display CCR9-dependent and -independent homing to the
small intestine. Blood 2006. 107:3447–3454.
33 Sun, J. C., Beilke, J. N., Bezman, N. A. and Lanier, L. L., Homeostatic
proliferation generates long-lived natural killer cells that respond against
viral infection. J. Exp. Med. 2011. 208:357–368.
34 Tarrio, M. L., Lee, S.-H., Fragoso, M. F., Sun, H.-W., Kanno, Y., O’Shea, J.
J. and Biron, C. A., Proliferation conditions promote intrinsic changes in
NK cells for an IL-10 response. J. Immunol. 2014. 193:354–363.
35 Mehrotra, P. T., Donnelly, R. P., Wong, S., Kanegane, H., Geremew, A.,
Mostowski, H. S., Furuke, K. et al., Production of IL-10 by human natural
killer cells stimulated with IL-2 and/or IL-12. J. Immunol. 1998. 160:2637–
2644.
36 Couper, K. N., Blount, D. G. and Riley, E. M., IL-10: the master regulator
of immunity to infection. J. Immunol. 2008. 180:5771–5777.
37 Higuma-Myojo, S., Sasaki, Y., Miyazaki, S., Sakai, M., Siozaki, A., Miwa,
N. and Saito, S., Cytokine profile of natural killer cells in early human
pregnancy. Am. J. Reprod. Immunol. 2005. 54:21–29.
38 Mandaric, S.,Walton, S. M., Ru¨licke, T., Richter, K., Girard-Madoux, M. J.
H., Clausen, B. E., Zurunic, A. et al., IL-10 suppression of NK/DC crosstalk
leads to poor priming of MCMV-specific CD4 T cells and prolongedMCMV
persistence. PLoS Pathog. 2012. 8.
39 Alter, G., Kavanagh, D., Rihn, S., Luteijn, R., Brooks, D., Oldstone, M.,
Van Lunzen, J. et al., IL-10 induces aberrant deletion of dendritic cells
by natural killer cells in the context of HIV infection. J. Clin. Invest. 2010.
120:1905.
40 Morandi, B., Mortara, L., Chiossone, L., Accolla, R. S., Mingari, M. C.,
Moretta, L., Moretta, A. et al., Dendritic cell editing by activated natural
killer cells results in amore protective cancer-specific immune response.
PLoS One 2012. 7:e39170.
41 Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L. and Vivier, E., Natural-
killer cells and dendritic cells: ‘l’union fait la force’. Blood 2005. 106:2252–
2258.
42 Wilson, J. L., Heffler, L. C., Charo, J., Scheynius, A., Bejarano, M. T.
and Ljunggren, H. G., Targeting of human dendritic cells by autologous
NK cells. J. Immunol. 1999. 163:6365–6370. https://doi.org/ji_v163n12p6365
[pii].
43 Conroy, M. J., Mac Nicholas, R., Grealy, R., Taylor, M., Otegbayo, J. A.,
O’Dea, S.,Mulcahy, F. et al., Circulating CD56dim natural killer cells and
CD56+ T cells that produce interferon-γ or interleukin-10 are expanded
in asymptomatic, E antigen-negative patients with persistent hepatitis B
virus infection. J. Viral Hepat. 2015. 22:335–345.
44 Perona-wright, G., Mohrs, K., Szaba, F. M., Kummer, L. W., Karp, C. L.,
Johnson, L. L. and Smiley, S. T., Systemic but not local infections elicit
immunosuppressive IL-10 production by Natural Killer cells. Cell Host
Microbe 2009. 6:503–512.
45 Zhang, Y.,Wallace, D. L., De Lara, C. M., Ghattas, H., Asquith, B.,Worth,
A., Griffin, G. E. et al., In vivo kinetics of human natural killer cells: the
effects of ageing and acute and chronic viral infection. Immunology 2007.
121:258–265.
46 Guethlein, L. A., Abi-Rached, L., Hammond, J. A. and Parham, P., The
expanded cattle KIR genes are orthologous to the conserved single-copy
KIR3DX1 gene of primates. Immunogenetics 2007. 59:517–522.
47 Thiant, S., Yakoub-Agha, I., Magro, L., Trauet, J., Coiteux, V., Jouet, J. P.,
Dessaint, J. P. et al., Plasma levels of IL-7 and IL-15 in the first month
after myeloablative BMT are predictive biomarkers of both acute GVHD
and relapse. Bone Marrow Transpl. 2010. 45:1546–1552.
48 Savani, B. N., Mielke, S., Rezvani, K., Montero, A., Yong, A. S., Wish, L.,
Superata, J. et al., Absolute lymphocyte count on day 30 is a surrogate
for robust hematopoietic recovery and strongly predicts outcome after
T cell-depleted allogeneic stem cell transplantation. Biol. Blood Marrow
Transplant. 2007. 13:1216–1223.
49 Petersen, S. L.,Madsen, H. O., Ryder, L. P., Svejgaard, A.,Masmas, T. N.,
Dickmeiss, E., Heilmann, C. et al., Chimerism studies in HLA-identical
nonmyeloablative hematopoietic stem cell transplantation point to the
donor CD8+ T-cell count on day +14 as a predictor of acute graft-versus-
host disease. Biol. Blood Marrow Transplant. 2004. 10:337–346.
50 Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., Apper-
ley, J. et al., Defining the intensity of conditioning regimens: working
definitions. Biol. Blood Marrow Transplant. 2009. 15:1628–1633.
51 Rowlings, P. A., Przepiorka, D., Klein, J. P., Gale, R. P., Passweg, J. R.,
Henslee-Downey, P. J., Cahn, J. Y. et al., IBMTR Severity Index for grading
acute graft-versus-host disease: retrospective comparison with Glucks-
berg grade. Br. J. Haematol. 1997. 97:855–864.
Abbreviations: Allo-SCT: allogeneic stem cell transplantation · CMV:
cytomegalovirus · GVHD: Graft versus host diseases · NK: natural killer
Full correspondence: Dr. Paul Moss, Institute of Immunology and
Immunotherapy, University of Birmingham, B15 2TT
e-mail: p.moss@bham.ac.uk
Received: 16/5/2017
Revised: 16/8/2017
Accepted: 18/9/2017
Accepted article online: 25/9/2017
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co.KGaA, Weinheim.
www.eji-journal.eu
